Author Archive: BIOtechNOW Editor

Worldwide Orphan Drug Market to Grow to $127 Billion by 2018

Infographic

The 2013 Orphan Drug Report from Evaluate, which launched today at the 2013 BIO international Convention, sheds light on the market dynamics of orphan drugs — pharmaceutical products aimed at rare diseases or disorders — projecting that sales will experience a compound annual growth rate of 7.4 percent between 2012 and 2018, nearly double that of the prescription drug market, excluding generics.  The report based on EvaluatePharma® data found that the worldwide orphan drug market Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Finding Biotech in the Silicon Prairie

BIO International Convention

The Silicon Prairie is about more than technology companies and Internet start-ups. In fact, the biotech industry in Illinois employs nearly 80,000 people, according to a recent analysis by Battelle, and their salaries are double the salary of the average private sector worker in the state. As biotech executives from across the globe descend upon McCormick Place this week for the annual BIO International Convention, they will have an opportunity to see that the Chicago Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Expanding Access to Orphan Drugs

Orphan Drugs

At present many orphan diseases do not have any licensed treatments, and for those conditions where there is a therapy, it is often the only therapy in the class that is available. However, this is not always the case. In the field of blood-plasma proteins, therapies to treat hemophilia, alpha-1 deficiency and primary immune deficiencies have multiple innovator versions in a therapeutic class. Often one product in the class has received an orphan designation and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Opening Up Innovation

Cancer

Open Innovation has become a major theme in the life sciences over the last couple of years. Most of the attention has focused on initiatives where big pharma offers access to non-core assets to outside researchers in the hope that they will develop them successfully or form collaborations. In Sweden, AstraZeneca have followed this path, but interest in the concept has spread further down the discovery chain, generating creative initiatives from universities, tech transfer organizations, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Our Health Care Ecosystem

Meekers

There are currently 907 drugs and vaccines targeting more than 100 diseases in development by U.S. biopharmaceutical companies. It is the first step on a path toward bringing much needed treatments to patients. However, with the current focus on the cost of health care, regulatory approval is not the final hurdle. Increasingly, the ability of patients to access new therapies is determined by those who pay for the treatments. Skyrocketing development costs, concerns about the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,